Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4658936 | 0.81 | PTGER1 (0.31) | PTGER1PTGER3 | |
| SCHEMBL13873909 | 0.75 | PTGER1 (0.36) | PTGER1PTGER3 | |
| SCHEMBL13873908 | 0.75 | PTGER1 (0.52) | PTGER1PTGER3 | |
| SCHEMBL4157602 | 0.73 | KDM4E (0.36) | AKR1C3AKR1C2PTGS2 | |
| SCHEMBL4658942 | 0.73 | ALPL (0.34) | — | |
| SCHEMBL4157349 | 0.72 | PTGER1 (0.34) | PTGER1PTGER3 | |
| SCHEMBL4160811 | 0.65 | PTGER1 (0.30) | PTGER1PTGER3 | |
| SCHEMBL21437678 | 0.63 | CHRM2 (0.48) | PTGER1PTGER3 | |
| SCHEMBL13039947 | 0.62 | CYP2D6 (0.47) | PTGER1PTGER3AKR1C3 | |
| SCHEMBL17180008 | 0.60 | PKM (0.50) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2001872-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885PTGER3 3/4885AKR1C3 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.